




Sanders-Brown Center on Aging

Please help us find a cure for Alzheimer's disease!

We have many opportunities for both normal elderly persons and those suffering from diseases such as Alzheimer's. Take a look below and see if you find an opportunity that is right for you.

Research Participation Opportunities



Sanders-Brown Research Volunteer Normal Control Group

This program studies normal healthy brain aging and early memory changes that may lead to Alzheimer's disease if unchecked. The goals of participation are to help us promote normal healthy brain aging for all. This group includes 500 cognitively normal elderly persons that participate in yearly memory testing and agree to donate brain tissue for research purposes at the time of their death. **For information call Diane at 859-323-6422 or Kathy at 859-257-5562**

African American Dementia Outreach Partnership


AADOP provides dementia education, training, and health services to the African American community who are at 15-100% greater risk than Caucasians for the development of Alzheimer's disease. Opportunities are available for both cognitively normal persons and those suffering from dementia. **For information call Jo at (859) 257-1412 ext 217**



Home-Based Assessment: Normal Adults Needed!

This clinical trial is studying tools developed for future use in a large-scale prevention trial for Alzheimer's disease. This trial is being conducted by the Alzheimer's Disease Cooperative Study Group at over 30 centers nationwide. Participants will be normal community-dwelling older adults. The study will look at the use of telephone based memory screening and the use of in-home computer systems to monitor memory & thinking skills over a 4 year study period. **For information call Diana at (859) 257-1412 ext 234**

For more information on these or other ongoing or planned clinical trials in Alzheimer's disease, please contact Diana at (859) 257-1412 ext 234



Telemedicine Assessment of Cognition in Rural KY: The TACK Study This study investigates the use of telemedicine for rural outreach and further examines clinical features of memory decline in persons living in rural or remote areas of KY. For information call Diana at (859) 257-1412 ext 234


Novel Anti-inflammatory, Anti-amyloid Strategy using RAGE (receptor for advanced glycation end-product) Inhibitors to Treat Alzheimer's Disease

The Alzheimer's Disease Cooperative Study group in conjunction with Pfizer Inc. will be testing a new medicine that may help slow or even stop the progression of Alzheimer's disease. RAGE inhibition is also being studied for the treatment of vascular disease that may contribute to the risk for stroke, heart attack, and other circulatory problems. The study is opening for enrollment for persons with mild to moderate Alzheimer's disease age 50 and older, over a 1 1/2 year period. For more information call Diana at (859) 257-1412 x234



Passive Immunization against Toxic β -amyloid in Alzheimer's disease: Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer's disease In an effort to make a safer vaccine for Alzheimer's disease and to test the effectiveness of this approach, Elan pharmaceuticals® has developed a humanized mouse monoclonal antibody that helps the brain destroy and eliminate toxic β -amyloid that may cause Alzheimer's disease. This study involves intravenous infusions of antibody over a 1 1/2 year study period. Preliminary studies have demonstrated the effectiveness and safety of this medication in Alzheimer's disease. Many researchers think this medicine will help to slow, stop, or even reverse the devastating effects of Alzheimer's disease on the brain. For information call Diana at (859) 257-1412 ext 234

Immunotherapy for Alzheimer's disease: Enrolling early 2008! Intravenous immunoglobulin has been shown in preliminary studies to potentially slow or even stop the progression of Alzheimer's disease. This upcoming trial will further investigate the disease modifying properties of IVIg in subjects with mild to moderate Alzheimer's disease over a 1 1/2 year period. The use of antibodies in this fashion represents one of the first attempts at passive immunization or vaccination for Alzheimer's disease. For information call Diana at (859) 257-1412 ext 234



University of Kentucky Alzheimer's Disease Center
Sanders-Brown Center on Aging
800 South Limestone Street, Lexington, KY 40536
Phone (859) 323-6040 Web: <http://www.mc.uky.edu/coa/>
Funded in part by the National Institute on Aging grant 1P30 AG028383

